Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

FDA Drug Recalls

775 recalls, newest first

Class II · Moderate risk

Clear Eyes

Failed Impurities Specification: Out-of-specification (OOS) stability test result was obtained for unspecified impurity.

Terminated Impurity / degradation Teva Pharmaceuticals USA Inc NDC 67172-504-01 D-0469-2023
Class II · Moderate risk

Carbidopa and Levodopa Tablets

Packaging defect: observed packaging defect, blister packaging inadequately sealed.

Terminated Packaging defect The Harvard Drug Group NDC 0904-7257-61 D-0432-2023
Class III · Low risk

Gabapentin Tablets

Presence of Foreign Tablets/Capsules: Pharmacist reported presence of some Gabapentin tablets 800 mg comingled in Gabapentin 600 mg 500 count bottles.

Terminated Particulate / foreign matter Sciegen Pharmaceuticals Inc D-0354-2023
Class II · Moderate risk

Testosterone Cypionate Injection

cGMP: complaints of crystals not redissolving into solution after warming and shaking the vials.

Terminated cGMP deviation Azurity Pharmaceuticals, Inc. NDC 52536-625-10 D-0489-2023
Class III · Low risk

Buprenorphine Transdermal System

Failed Impurities/Degradation Specifications: Out of specification for related substance 10-hydroxy buprenorphine N-Oxide results generated at the 18-month stability timepoint.

Terminated Impurity / degradation AVEVA Drug Delivery Systems, Inc. NDC 60505-7079-05 D-0466-2023
Class III · Low risk

Buprenorphine Transdermal System

Failed Impurities/Degradation Specifications: Out of specification for related substance 10-hydroxy buprenorphine N-Oxide results generated at the 18-month stability timepoint.

Terminated Impurity / degradation AVEVA Drug Delivery Systems, Inc. NDC 60505-7077-05 D-0465-2023

Recalls by year